Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Stock Popped Today

By Keith Speights - May 7, 2021 at 3:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

BioNTech and Pfizer announced a filing for full FDA approval of their COVID-19 vaccine.

What happened

Shares of BioNTech (BNTX 0.21%) were jumping 8.6% as of 3:13 p.m. EDT on Friday. The nice pop came after the biotech and its partner Pfizer (PFE 1.17%) announced that they have initiated a rolling submission of a regulatory application with the Food and Drug Administration for approval of their COVID-19 vaccine.

So what

The Pfizer-BioNTech COVID-19 vaccine became the first vaccine to win Emergency Use Authorization (EUA) from the FDA in December 2020. The two partners are also the first to file for full FDA approval for a COVID-19 vaccine.

Vaccine vials

Image source: Getty Images.

Full FDA approval will be required for the company's COVID-19 vaccine to remain on the market once the pandemic ends and the EUA program is concluded. The process for full approval will take a longer period of time, typically 10 months. However, Pfizer and BioNTech have requested Priority Review. If this request is granted, the FDA will make an approval decision within six months of the acceptance of the regulatory filing.

Today's news is just the latest in a string of positive developments for BioNTech. The stock is now up more than 120% year to date.

Now what

The next step for BioNTech and Pfizer is to submit the manufacturing and facility data that the FDA requires for review. The companies also await an FDA decision on expanding the EUA currently in place for their COVID-19 vaccine to include adolescents ages 12 to 15. 

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$147.92 (0.21%) $0.31
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.15 (1.17%) $0.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.